论文部分内容阅读
目的:观察血脂康、舒降之和肝得健治疗脂肪肝的疗效及毒副作用。方法:选择脂肪肝158例,分为血脂康、舒降之和肝得健治疗三组。通过用药前后肝功能、血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL—C)、高密度脂蛋白胆固醇(HDL—C)以及B超中肝脏形态学改变进行观察。结果:经过用药半年后血脂康治疗组总有效率90.77％。舒降之组总有效率66.67％。肝得健组总有效率52.08％。结论:血脂康具有调整脂肪、抑制脂肪肝形成的作用。其疗效优于舒降之及肝得健,而舒降之的疗效与肝得健差不多。因此血脂康可作为治疗脂肪肝的一种新药。
Objective: To observe the efficacy and toxic side effects of Xuezhikang, Shuzhengzhi and Hede Jian in the treatment of fatty liver. Methods: 158 cases of fatty liver were selected and divided into three groups: Xuezhikang, Shuzheng and Hede Jian. The changes of liver function, serum total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) Observed. Results: After six months of treatment, the total effective rate of Xuezhikang treatment group was 90.77%. Shu drop the total effective rate of 66.67%. Liver health group total effective rate of 52.08%. Conclusion: Xuezhikang can regulate fat and inhibit the formation of fatty liver. Its efficacy is better than Shu and the liver is healthy, and the effect of Shu and the liver is almost the same health. Therefore, Xuezhikang can be used as a new drug for the treatment of fatty liver.